MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, CHRS made $12,310K in revenue. -$38,327K in net income. Net profit margin of -311.35%.

Income Overview

Revenue
$12,310K
Net Income
-$38,327K
Net Profit Margin
-311.35%
EPS
-$0.28
Unit: Thousand (K) dollars
Revenue Breakdown
    • Toripalimab
    • Product And Service Other

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net revenue
12,310 12,748 11,571 10,254
Cost of goods sold
3,814 4,045 3,721 3,395
Research and development
21,543 30,974 27,252 26,306
Selling, general and administrative
23,104 23,609 24,931 26,039
Total costs and expenses
48,461 58,628 55,904 55,740
Loss from operations
-36,151 -45,880 -44,333 -45,486
Interest expense
2,186 2,249 2,325 2,277
Loss on debt extinguishment
-0 --
Other income (expense), net
1,402 1,782 2,141 2,901
Loss from continuing operations before income taxes
-36,935 -46,347 -44,517 -44,862
Net loss from continuing operations
-36,935 -46,347 -44,517 -44,862
Net revenue
-899 25,978* 10,663 -
Cost of goods sold
55 16,503* 287 -
Research and development
--985* 564 -
Selling, general and administrative
50 7,567* 326 -
Total costs and expenses
105 23,084* 1,177 -
Income from operations
-1,004 2,894* 9,486 -
Interest expense
-2,023* --
Gain on sale transactions, net
-388 -886* -422 -
Gain on debt extinguishment
-20,572* --
Other income (expense), net
--11,852* -78 -
Net income from discontinued operations before income taxes
-1,392 8,704 8,986 -
Net loss from discontinued operations, net of tax (note 6)
-1,392 8,704 8,986 342,629
Net gain
-38,327 -37,643 -35,531 297,767
Basic EPS
-0.28 -0.313 -0.31 2.57
Diluted EPS
-0.28 -0.313 -0.31 2.57
Basic Average Shares
136,398,303 120,409,168 116,229,170 116,077,710
Diluted Average Shares
136,398,303 120,409,168 116,229,170 116,077,710
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net gain-$38,327K (32.25%↑ Y/Y)Net loss fromcontinuing operations-$36,935K (22.07%↑ Y/Y)Net loss fromdiscontinued operations, net...-$1,392K (84.82%↑ Y/Y)Loss from continuingoperations before income...-$36,935K (22.07%↑ Y/Y)Net income fromdiscontinued operations...-$1,392K Other income(expense), net$1,402K (649.73%↑ Y/Y)Toripalimab$11,803K (60.63%↑ Y/Y)Product And ServiceOther$507K (101.99%↑ Y/Y)Loss from operations-$36,151K (20.43%↑ Y/Y)Interest expense$2,186K (1.67%↑ Y/Y)Income from operations-$1,004K (-117.91%↓ Y/Y)Gain on saletransactions, net-$388K Net revenue$12,310K (61.99%↑ Y/Y)Total costs andexpenses$48,461K (-8.62%↓ Y/Y)Net revenue-$899K (-102.85%↓ Y/Y)Total costs andexpenses$105K (-99.60%↓ Y/Y)Selling, general andadministrative$23,104K (-11.22%↓ Y/Y)Research and development$21,543K (-11.55%↓ Y/Y)Cost of goods sold$3,814K (43.76%↑ Y/Y)Cost of goods sold$55K (-99.72%↓ Y/Y)Selling, general andadministrative$50K (-99.30%↓ Y/Y)

Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. (CHRS)